NCT06285812View on ClinicalTrials.gov

Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children

Active, not recruitingOBSERVATIONAL
Enrollment

700

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 30, 2025

Conditions
Otitis Media Acute
Interventions
DEVICE

OtoSight Middle Ear Scope

Subjects will be evaluated with the OtoSight Middle Ear Scope

Trial Locations (7)

14620

Trillim Health, Rochester

20010

Children's National Hospital, Washington D.C.

29118

Carolina ENT, Orangeburg

32802

AdventHealth Children's Research, Orlando

33175

Abba Medical Group LLC, Miami

37813

HealthStar Physicians, Morristown

97030

Cyn3rgy Research, Gresham

Sponsors

Lead Sponsor

PhotoniCare, Inc.
All Listed Sponsors
collaborator

TTi Health Research & Economics

UNKNOWN

lead

PhotoniCare, Inc.

INDUSTRY

NCT06285812 - Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children | Biotech Hunter | Biotech Hunter